Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05740332 · ClinicalTrials.gov registry record · Phase 4

Wet Time for a Foam Hand Sanitizer

A Phase 4 study, sponsored by Medline Industries.

Completed
Registry status
Phase 4
Development phase
46
Enrollment target

NCT05740332: Completed Phase 4 study, sponsored by Medline Industries.

NCT05740332 is a Phase 4 study that has completed, run by Medline Industries. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05740332, a Phase 4 study, has completed, sponsored by Medline Industries.

COMPLETED
Registry status
Phase 4
Development phase
46 participants
Enrollment target

Study Summary

Hand sanitizers are a standard of hygiene requirements. They must be effective at reducing germ count on the hands while ideally providing emollients to moisturize the skin after use. Spectrum™ Advanced Hand Sanitizer Foam (70%) (hereby referred to as Spectrum Advanced Foam) kills over 99.99% of germs within 15 seconds while boasting double digit increases in hand moisture after two weeks of use. In 2002 and 2009 the Center for Disease Control and Prevention (CDC) and World Health Organization (WHO) published guidance that hands should remain wet for at least 15 seconds while being rubbed together after application of an alcohol-based hand rub, though the recommendations do not specify the volume of product to be apply. This study will evaluate the "wet time" of Spectrum Advanced Foam, which will be defined as the length of time in which the sanitizer foam stays wet on the hands while the participant rubs their hands with the foam sanitizer. The participant will first be asked to wash and dry their hands. Participants will review the appropriate hand sanitizer application steps, as detailed by the WHO guidance. Then, a 1.0 milliliter (mL) aliquot of Spectrum Advanced Foam will be dispensed from an automated dispenser to the participant's hands. The participant will be asked to rub their hands together following the WHO method for hand sanitizer application until they declare the product has dried sufficiently for the donning of medical gloves. Study personnel will measure the wet time of Spectrum Advanced foam using a stopwatch. If the 1.0 ml aliquot does not yield sufficient results to meet WHO guidelines then a 1.4 ml aliquot will be tested, however this was not the case for our study.

Primary Outcome

To determine the duration of time during which a 1.0 mL aliquot of Spectrum Advanced Hand Sanitizer Foam remains wet under conventional use conditions.

Interventions

  • DRUG Alcohol hand sanitizer foam

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2022-12-12
Est. Completion 2023-01-12
Phase Phase 4
Medline Industries

24 total trials

What the finished NCT05740332 record still lists

NCT05740332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Alcohol hand sanitizer foam is the first listed.

NCT05740332 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05740332 about?

NCT05740332 is a clinical study titled "Wet Time for a Foam Hand Sanitizer". Hand sanitizers are a standard of hygiene requirements. They must be effective at reducing germ count on the hands while ideally providing emollients to moisturize the skin after use. Spectrum™ Advanced Hand Sanitizer Foam (70%) (hereby referred to as Spectrum Advanced Foam) kills over 99.99% of ger...

What is the current status of trial NCT05740332?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2022-12-12. Estimated completion is 2023-01-12.

What interventions are being tested in trial NCT05740332?

The interventions under investigation include: Alcohol hand sanitizer foam (DRUG).

Who is sponsoring clinical trial NCT05740332?

This trial is sponsored by Medline Industries, which has 24 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05740332's enrollment target sits among peer trials

46 1348th of 2000 higher than 647 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05740332, the US trial registry maintained by the National Library of Medicine. NCT05740332 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.